Speaker Profile
CEO, Cordance Medical
Biography
Ryan Dittamore has developed and commercialized multiple oncology products utilized in medicine today. Most recently, he was CBO of Decipher Biosciences, and previously Chief of Medical Innovation at Epic Sciences, where he led the clinical development, reimbursement, guideline support, and commercial partnering of the AR-V7 test (the first predictive test in prostate cancer). Ryan has also held roles at Roche Dx (Ventana), Genisphere (Code Biotherapeutics), and Bio-Rad. Cumulatively, he has partnered with over 60 biopharma companies, is the author of over 30 peer-reviewed publications, and inventor of 12 patents issued and pending.
Clinical Dx Showcase:
Cordance Medical
Cordance Medical is enabling precision medicine for brain tumors. We are developing a device that opens the Blood-Brain Barrier in a temporary, non-invasive, and patient-friendly manner enabling liquid biopsies and improved drug delivery.
Non-invasive BBB Penetrance to Enable Precision Medicine
An overview of our non-invasive, globally scalable Blood-Brain Barrier (BBB) penetrance device to enable liquid biopsies for patients with primary brain tumors and brain metastasis to receive a contemporary liquid biopsy and improved drug delivery.
Session Abstract – PMWC 2022 Silicon Valley
The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative
